Establishing HIV-1 chromatin in resting T cells: Vpr, latency, and H2A.Z
Establishing HIV-1 chromatin in resting T cells: Vpr, latency, and H2A.Z
批准号:
10558472
负责人:
DAVID N LEVY
金额:
$39.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-02-01 至 2025-01-31
关键词:
ApoptosisBindingBiological AssayCD4 Positive T LymphocytesCell Cycle ArrestCellsChromatinChromatin Remodeling FactorChromatin StructureChronicComplexDNADNA DamageDataDisputesEpigenetic ProcessEventEvolutionGene ExpressionGenesGenetic TranscriptionGleanHIVHIV InfectionsHIV-1Histone DeacetylationHistone H2AHistonesImmediate-Early ProteinsInfectionLentivirusMediatingModificationMolecularNucleosomesPathway interactionsPharmaceutical PreparationsPositive Transcriptional Elongation Factor BPost-Translational Protein ProcessingProcessPromoter RegionsProtein IsoformsProteinsProvirusesRNARegulationReporterRepressionRestReverse TranscriptionRoleSignal TransductionStimulusStructureT-Cell ActivationT-LymphocyteTestingTimeTransactivationTranscriptional RegulationTransformed Cell LineViralViral GenomeViral ProteinsVirionVirusVirus ReplicationWorkdesignepigenetic regulationhistone methylationinsightlatent infectionmutantnovelpermissivenesspreservationprogramspromoterpurgerecruitresponsesmall molecule inhibitortherapeutic developmenttranscriptome sequencingvpr Gene Products
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Latent HIV infection of resting CD4 T cells present a formidable challenge in the pursuit of treatments to purge
HIV from the body. Latency is established and regulated in large part through the modifications of the
nucleosomes that are bound around the viral promoter region. Drugs that reactivate latent HIV must influence
these structures in order to allow HIV transcription and virus expression. However, for unknown reasons not all
intact proviruses respond to latency reversing agents and thus present a particularly troublesome barrier to cure.
A greater understanding of the regulation of HIV-1 chromatin, the installation of nucleosomes and their histone
post translational modifications (PTM) will contribute greatly to the development of therapeutic control over HIV-
1 latency. This project seeks such an understanding and builds upon extensive preliminary studies revealing
important new insights into these processes. For the first time we investigate the initial stages of HIV-1 chromatin
installation, finding that it occurs either contemporaneously or soon after reverse transcription, and before
integration into the cellular DNA. We find that repressive chromatin is installed in the absence of the viral protein
Vpr being delivered in the virion. Virion Vpr dramatically increases the number of transcriptionally active
proviruses in the first 4 days after infection of resting CD4 T cells. When Vpr is present, the nucleosomes that
control HIV expression are modified in ways that facilitate HIV replication and block installation of repressive
chromatin. For example, the alternate histone H2A.Z is installed only when virion Vpr is available, and H2A.Z is
a central organizer of paused but responsive promoters. Without Vpr, the chromatin of latent proviruses takes
on a more repressed structure, resulting in more proviruses that do not respond to latency reversing agents.
Novel RNA-seq data demonstrate that virion Vpr reprograms gene expression pathways central to chromatin
organization and transcriptional regulation. This project will describe both the initial steps in HIV chromatization
and the long term processes that lead to reversible latency and irreversible repression. Aim 1 will systematically
analyze early proviral chromatin in resting CD4 T cells and the influence of Vpr and Tat-directed transcription on
the epigenetic landscape. Our central hypothesis is that Vpr directs installation of the transcriptional pre-initiation
complex for basal pre-Tat transcription in resting T cells. Aim 2 will analyze Vpr-dependent pathways leading to
these structures. RNA-seq data will be expanded and used to study novel Vpr targets of regulation, and known
Vpr pathways will be investigated for their influence on early events. Aim 3 will examine long term infection and
latency under the influence the structures and pathways gleaned from Aims 1 and 2. Our hypothesis is that Vpr
protects the provirus from epigenetic repression and irreversible latency. The proposed studies will provide much
needed information that will assist in the development of therapeutics that can purge HIV from the body or
permanently repress virus replication without continual antiviral treatments.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
Multiple infection of cells changes the dynamics of basic viral evolutionary processes
细胞的多重感染改变了基本病毒进化过程的动态
DOI:
10.1002/evl3.95
发表时间:
2019
期刊:
Evolution Letters
影响因子:
5
作者:
[Wodarz, Dominik, Levy, David N., Komarova, Natalia L.]
通讯作者:
Komarova, Natalia L.
DOI:
10.1186/s12977-019-0479-9
发表时间:
2019-06
期刊:
Retrovirology
影响因子:
3.3
作者:
[B. Trinité;Hongtao Zhang;D. N. Levy]
通讯作者:
B. Trinité;Hongtao Zhang;D. N. Levy
DOI:
10.1073/pnas.1916054117
发表时间:
2020-04-28
期刊:
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
影响因子:
11.1
作者:
[Fu, Yajing, He, Sijia, Wu, Yuntao]
通讯作者:
Wu, Yuntao
Probing the unique attributes of the naïve reservoir
-
批准号:10409284
-
项目类别:
-
资助金额:$83.11万
-
财政年份:2022
-
负责人:DAVID N LEVY
-
依托单位:
Probing the unique attributes of the naïve reservoir
-
批准号:10663946
-
项目类别:
-
资助金额:$79.38万
-
财政年份:2022
-
负责人:DAVID N LEVY
-
依托单位:
Establishing HIV-1 chromatin in resting T cells: Vpr, latency, and H2A.Z
-
批准号:10329921
-
项目类别:
-
资助金额:$39.63万
-
财政年份:2019
-
负责人:DAVID N LEVY
-
依托单位:
The contribution of unintegrated HIV-1 to latency and to models of latency
-
批准号:9075588
-
项目类别:
-
资助金额:$39.63万
-
财政年份:2015
-
负责人:DAVID N LEVY
-
依托单位:
HIV-1 Replication Without Integration
-
批准号:8679470
-
项目类别:
-
资助金额:$22.21万
-
财政年份:2013
-
负责人:DAVID N LEVY
-
依托单位:
Viruis Dynamics and Multiple Infection of Cells: Computational and Experimental A
-
批准号:8188288
-
项目类别:
-
资助金额:$38.9万
-
财政年份:2011
-
负责人:DAVID N LEVY
-
依托单位:
Viruis Dynamics and Multiple Infection of Cells: Computational and Experimental A
-
批准号:8510568
-
项目类别:
-
资助金额:$35.19万
-
财政年份:2011
-
负责人:DAVID N LEVY
-
依托单位:
Viruis Dynamics and Multiple Infection of Cells: Computational and Experimental A
-
批准号:8698706
-
项目类别:
-
资助金额:$37.33万
-
财政年份:2011
-
负责人:DAVID N LEVY
-
依托单位:
Viruis Dynamics and Multiple Infection of Cells: Computational and Experimental A
-
批准号:8309952
-
项目类别:
-
资助金额:$37.51万
-
财政年份:2011
-
负责人:DAVID N LEVY
-
依托单位:
HIV-1 Replication Without Integration
-
批准号:8432850
-
项目类别:
-
资助金额:$34.82万
-
财政年份:2009
-
负责人:DAVID N LEVY
-
依托单位:
HIV-1 Replication Without Integration
-
批准号:8033735
-
项目类别:
-
资助金额:$37.58万
-
财政年份:2009
-
负责人:DAVID N LEVY
-
依托单位:
HIV-1 Replication Without Integration
-
批准号:8225345
-
项目类别:
-
资助金额:$37.04万
-
财政年份:2009
-
负责人:DAVID N LEVY
-
依托单位:
HIV-1 Replication Without Integration
-
批准号:7686666
-
项目类别:
-
资助金额:$36.39万
-
财政年份:2009
-
负责人:DAVID N LEVY
-
依托单位:
HIV-1 Replication Without Integration
-
批准号:7766221
-
项目类别:
-
资助金额:$37.7万
-
财政年份:2009
-
负责人:DAVID N LEVY
-
依托单位:
HIV-1 Recombination In Natural Target Cells
-
批准号:6918638
-
项目类别:
-
资助金额:$7.97万
-
财政年份:2004
-
负责人:DAVID N LEVY
-
依托单位:
HIV-1 Recombination In Natural Target Cells
-
批准号:7302972
-
项目类别:
-
资助金额:$13.04万
-
财政年份:2004
-
负责人:DAVID N LEVY
-
依托单位:
HIV-1 Recombination In Natural Target Cells
-
批准号:6842333
-
项目类别:
-
资助金额:$20.58万
-
财政年份:2004
-
负责人:DAVID N LEVY
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: